While the Medicare Part D prescription drug program has been a U.S. success story in many ways, with more than 73 percent of Medicare beneficiaries enrolling in the plans last year, changes to the benefit design and the growing use of high-priced drugs could be eroding incentives to manage the program's costs, the Medicare Payment Advisory Commission (MedPAC) told Congress in its annual report.